loading
Relay Therapeutics Inc stock is traded at $2.86, with a volume of 420.66K. It is up +0.18% in the last 24 hours and down -8.36% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$2.845
Open:
$2.78
24h Volume:
420.66K
Relative Volume:
0.17
Market Cap:
$489.49M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.0214
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+1.42%
1M Performance:
-8.36%
6M Performance:
-40.00%
1Y Performance:
-59.17%
1-Day Range:
Value
$2.75
$2.90
1-Week Range:
Value
$2.75
$3.16
52-Week Range:
Value
$1.775
$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name
Name
Relay Therapeutics Inc
Name
Phone
617-370-8837
Name
Address
399 BINNEY STREET, CAMBRIDGE
Name
Employee
259
Name
Twitter
Name
Next Earnings Date
2025-02-21
Name
Latest SEC Filings
Name
RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RLAY
Relay Therapeutics Inc
2.855 478.33M 25.55M -341.97M -304.44M -2.80
Biotechnology icon
ONC
Beigene Ltd Adr
241.48 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.98 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.31 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.78 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.84 5.92B 0 -153.72M -103.81M -2.00

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-25 Initiated Wells Fargo Equal Weight
Sep-10-24 Resumed Goldman Buy
Sep-10-24 Upgrade Jefferies Hold → Buy
Sep-10-24 Downgrade Oppenheimer Outperform → Perform
May-10-24 Upgrade Barclays Equal Weight → Overweight
Apr-20-23 Upgrade Jefferies Underperform → Hold
Apr-19-23 Upgrade Raymond James Outperform → Strong Buy
Apr-13-23 Initiated Raymond James Outperform
Feb-03-23 Initiated Oppenheimer Outperform
Sep-30-22 Initiated Barclays Equal Weight
Sep-02-22 Initiated Stifel Buy
Jun-06-22 Initiated Jefferies Underperform
Feb-01-22 Initiated Berenberg Buy
Jul-21-21 Initiated BofA Securities Buy
Dec-15-20 Reiterated H.C. Wainwright Buy
Dec-08-20 Initiated JMP Securities Mkt Outperform
Nov-05-20 Initiated H.C. Wainwright Buy
Aug-10-20 Initiated Cowen Outperform
Aug-10-20 Initiated Goldman Buy
Aug-10-20 Initiated Guggenheim Buy
Aug-10-20 Initiated JP Morgan Neutral
View All

Relay Therapeutics Inc Stock (RLAY) Latest News

pulisher
May 22, 2025

Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 22, 2025
pulisher
May 21, 2025

BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 21, 2025
pulisher
May 17, 2025

Stifel Financial Corp Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 17, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 16, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 14, 2025

Transcript : Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey

May 12, 2025
pulisher
May 12, 2025

HC Wainwright Issues Optimistic Forecast for RLAY Earnings - Defense World

May 12, 2025
pulisher
May 11, 2025

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN

May 11, 2025
pulisher
May 11, 2025

89,949 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by First Trust Advisors LP - Defense World

May 11, 2025
pulisher
May 10, 2025

Dimensional Fund Advisors LP Grows Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 10, 2025
pulisher
May 09, 2025

Q2 EPS Estimate for Relay Therapeutics Lowered by Analyst - Defense World

May 09, 2025
pulisher
May 08, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Hsbc Holdings PLC Has $458,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - The AM Reporter

May 08, 2025
pulisher
May 08, 2025

MetLife Investment Management LLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 08, 2025
pulisher
May 07, 2025

Guggenheim Lowers Price Target for Relay Therapeutics (RLAY) to $10.00 | RLAY Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Relay Therapeutics (RLAY) Stock Target Reduced Amid Strategic Changes and Progress | RLAY Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Marshall Wace LLP Lowers Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 07, 2025
pulisher
May 07, 2025

Raymond James Financial Inc. Takes $779,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 07, 2025
pulisher
May 07, 2025

Wells Fargo & Company MN Decreases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 07, 2025
pulisher
May 06, 2025

Relay Therapeutics Inc (RLAY) Q1 2025 Earnings: EPS Loss of $0.4 - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Relay Therapeutics (RLAY) Reports Decline in Q1 Revenue | RLAY S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Relay Therapeutics Extends Cash Runway and Advances Clinical Trials - TipRanks

May 06, 2025
pulisher
May 05, 2025

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates | RLAY Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Relay Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2025
pulisher
May 05, 2025

Relay Therapeutics, Inc. SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Relay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial Advancements - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Barclays PLC Has $1.29 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 05, 2025
pulisher
May 04, 2025

Invesco Ltd. Acquires 5,261 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 04, 2025
pulisher
May 02, 2025

There Is A Lot Of Upside Potential For Relay Therapeutics Inc(NASDAQ: RLAY) - Stocksregister

May 02, 2025
pulisher
May 01, 2025

why Relay Therapeutics Inc [RLAY] is a Good Choice for Investors After New Price Target of $17.40 - dbtnews.com

May 01, 2025
pulisher
May 01, 2025

Relay Therapeutics executive sells $36,540 in stock By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Relay Therapeutics executive sells $36,540 in stock - Investing.com Australia

May 01, 2025
pulisher
May 01, 2025

LPL Financial LLC Sells 6,564 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 01, 2025
pulisher
May 01, 2025

Relay Therapeutics president sells $95,381 in stock By Investing.com - Investing.com South Africa

May 01, 2025
pulisher
May 01, 2025

Relay Therapeutics chief legal officer sells $44,040 in stock By Investing.com - Investing.com South Africa

May 01, 2025
pulisher
May 01, 2025

Relay Therapeutics CFO sells shares worth $44,246 By Investing.com - Investing.com South Africa

May 01, 2025
pulisher
Apr 30, 2025

Relay Therapeutics Inc Stock: Executives Sell Shares Amid Mixed Signals - sharewise

Apr 30, 2025
pulisher
Apr 30, 2025

Relay Therapeutics president sells $95,381 in stock - Investing.com Australia

Apr 30, 2025
pulisher
Apr 30, 2025

Relay Therapeutics CFO sells shares worth $44,246 - Investing.com Australia

Apr 30, 2025
pulisher
Apr 30, 2025

Relay Therapeutics chief legal officer sells $44,040 in stock - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

Relay Therapeutics Executives Sell Shares to Cover Tax Obligations and Under Trading Plan - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

Trading Day Review: Relay Therapeutics Inc (RLAY) Loses Momentum, Closing at 3.10 - DWinneX

Apr 30, 2025

Relay Therapeutics Inc Stock (RLAY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Relay Therapeutics Inc Stock (RLAY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Rahmer Peter
See remarks
Apr 28 '25
Sale
3.17
1,364
4,324
400,820
Catinazzo Thomas
Chief Financial Officer
Apr 30 '25
Sale
3.00
12,943
38,829
355,376
Catinazzo Thomas
Chief Financial Officer
Apr 29 '25
Sale
3.23
3,558
11,492
368,319
Catinazzo Thomas
Chief Financial Officer
Apr 28 '25
Sale
3.17
2,690
8,527
371,877
Bergstrom Donald A
President, R&D
Apr 30 '25
Sale
3.00
27,472
82,416
583,490
Bergstrom Donald A
President, R&D
Apr 28 '25
Sale
3.17
4,090
12,965
610,962
Adams Brian
Chief Legal Officer
Apr 30 '25
Sale
3.00
12,943
38,829
391,385
Adams Brian
Chief Legal Officer
Apr 28 '25
Sale
3.17
1,644
5,211
404,328
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Cap:     |  Volume (24h):